MicroRNAs miR-146a/b negatively modulate the senescence-associated












































Cellular senescence is a cell fate program triggered by 
potentially oncogenic stimuli and stresses that prevent 
aged or abnormal cells from further proliferation [1, 2].  
Several stimuli, including repeated proliferation, growth 
stimulation coordinated with cell-cycle arrest, DNA 
damage and expression of activated oncogenes cause 
mammalian cells to enter into the essentially irrevers-
ible growth senescent arrest and acquire the morpho-
logical and behavioral features of senescent cells  [3-5]. 
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secretion  of  the  inflammatory  mediators  IL‐  6  and  IL‐8  which  are  part  of  a  larger  senescence  associated  secretory
phenotype  (SASP).  We  screened  quiescent  and  senescent  human  fibroblasts  for  differentially  expressed  microRNAS
(miRNAs) and found that miRNAs 146a and 146b (miR‐146a/b) were significantly elevated during senescence.  We suggest












Senescent cells have been shown to accumulate in a 
variety of  aging tissues as well as several premalignant 
and malignant lesions [1].  Because cellular senescence 
eliminates the proliferative capacity of damaged cells it 
is a potent tumor suppressing mechanism [1, 6].   
However senescence also prevents the replacement of 
cells lost owing to age, injury or apoptosis.  Thus, the 
senescence response is likely a tradeoff between tumor 
suppression and tissue regeneration.  Senescence may 
therefore be considered an example of evolutionary 
antagonistic pleiotropy, whereby a trait that confers a 
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may be retained even though it also has deleterious 
effects later in life [7]. 
 
Senescent human cells exhibit numerous changes in 
gene expression, many of which relate to the growth 
arrest [8].  Senescent cells also develop a senescence- 
associated secretory phenotype (SASP) [9].  The SASP 
is characterized by the secretion of a wide range of 
growth factors, cytokines, extracellular matrix proteins 
and degradative enzymes, most of which can alter the 
local tissue microenvironment [9-13].  The SASP is 
controlled in a modular fashion:  for example, the DNA 
damage response kinase ATM is required for the 
upregulation of some, but not all, SASP factors [14].   
Of particular interest SASP is characterized by high 
level secretion of the cytokines, IL-6 and IL-8, which 
are key mediators of inflammation.  Inflammation is 
important for development of cancer as well as many 
other age-related diseases [15].  Furthermore, IL-6 and 
IL-8 were recently shown to reinforce the senescent 
growth arrest [15-17].  Thus, understanding the 
mechanisms that regulate IL-6 and IL-8 in association 
with senescence is important for understanding 
biological processes as diverse as tumor suppression 
and the development of age-related diseases, including 
cancer.   
 
Recent studies have identified microRNAs (miRNAs) 
as important regulators of diverse biological processes.  
miRNAs are ~22 nucleotide non-coding regulatory 
RNAs that are evolutionary conserved from nematodes 
to humans [18, 19].  Primary miRNAs are initially 
transcribed by RNA polymerase II as larger precursors, 
which are then cleaved by a nuclear complex containing 
the ribonuclease Drosha and DCGR8.  The cleaved 
product is a hairpin RNA ~65 nucleotides in length 
known as the pre-miRNA [20].  The pre-miRNA is 
further processed to the mature miRNA by the cytosolic 
enzyme Dicer.  The mature miRNA is then incorporated 
into the RNA-induced silencing complex (RISC). The 
miRNA-RISC complex binds to target messenger RNAs 
(mRNAs), often in the 3' untranslated regions, and 
either promotes mRNA degradation or translational 
repression [21-23].  Each miRNA has the potential to 
regulate the expression of multiple mRNA targets.   
 
miRNAs regulate a broad range of phenotypes 
including embryonic development, cell proliferation, 
differentiation and apoptosis [24-27].   miRNAs also 
control various activities of the immune system [28-30].  
Recent studies show that miRNAs are important 
etiological or facilitating factors in the pathogenesis of 
several diseases, including cancer, diabetes, rheumatoid 
arthritis, and Alzheimer’s disease [31-35].   
miRNAs have also been implicated in the control of 
aging and cellular senescence.  Mutation of miR-lin-4 in 
C.elegans  dramatically shortens life span [36].     
Additionally members of the miR-34 family of miRNAs 
were recently shown to suppress cell proliferation and 
be direct targets of the p53 tumor suppressor protein 
which is required for the senescence growth arrest [31, 
37].  Indeed, overexpression of miR-34a in normal 
human IMR90 fibroblast caused a senescence growth 
arrest [37].  Similarly the MDM2 inhibitor Nutlin3A 
induced miR-34 and senescence in human fibroblasts 
via activation of p53 [38].   In mouse embryonic 
fibroblasts (MEFs), miR-20a induced senescence, in 
this case by upregulating the p16INK4A tumor 
suppressor protein [39].  Finally ablation of Dicer in 
MEF’s induced senescence by upregulating p53, 
indicating that miRNAs play both positive and negative 
roles in regulating the senescence arrest [40].  In 
contrast to a rising understanding of how miRNAs 
modulate the senescence growth arrest, virtually 
nothing is known about whether or how miRNAs 
regulate any component of the SASP.  
 
Here we report, that the levels of two related miRNAs, 
miR-146a and 146b (miR-146a/b), increase in senescent 
human fibroblasts in an interleukin IL1α dependent 
manner, but only when high levels of IL-6 and IL-8 
secretion accompany senescence.  In the context of the 
SASP, we propose that increased expression of miR-
146a/b serves to restrain excessive secretion of the 
inflammatory cytokines IL-6 and IL-8, thereby limiting 




Induction of miR-146a and miR-146b by senescent 
human HCA2 fibroblasts 
 
In screening arrays of known miRNAS for those that 
are differentially expressed by quiescent versus 
senescent cells (C. Patil, manuscript in preparation), we 
found that miR-146a and miR-146b were expressed at 
significantly higher levels by senescent HCA2 cells, 
which are normal human fibroblasts from neonatal 
foreskin.  This was true whether senescence was 
induced by a DNA damaging agent (bleomycin, which 
causes DNA double strand breaks) (DS) or replicative 
exhaustion (RS).  We validated the array results for 
miR-146a expression by northern analysis.  miR-146a 
was readily detectable in senescent cells, but was 
undetectable in proliferating (P) or quiescent (Q) cells 
(Figure 1A).  In these and subsequent samples, 
senescence was confirmed by the low percentage of 
proliferating (BrdU–incorporating) cells and high 
percentage of cells that stained positive for the 
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1; Experimental Procedures).  Because quiescent cells, 
which are not senescent but rather temporarily growth 
arrested, expressed low to undetectable levels of miR-
146a, as did proliferating presenescent cells, we conclude 
that robust expression of miR-146a is specifically 
associated with senescence and not simply with growth 
arrest.  In the experiments that follow, we used pro-
liferating cells as a negative control for miR-146a/b 













































We investigated the kinetics of induction of miR-146a/b 
expression following induction of senescence by 
different stimuli.  Following a senescence-inducing 
dose of the DNA damaging agent bleomycin, miR-
146a/b was first detected approximately 12 days later 
(Figure 1B).  By comparison, the SASP is first evident 
3-4 days after a senescence-inducing dose of DNA 
damage, and completely established within 5-7 days 
after senescence induction [9, 14]  Thus, the levels of 
miRNA-146a/b remained undetectable or very low 
during the interval in which the SASP developed in 
response to DNA damage (not shown), and were 
detected by northern analysis only several days later.   
By 25 days after senescence was induced by DNA 
damage, the levels of miRNA-146a/b were maximal 
(Figure 1B).  At this time point, the few cells that were 
able to repair the damage and resume growth comprised 
only a small fraction of the population and thus the 
population remained largely senescent with ~5% BrdU 
incorporation and 85% SA- βgal activity.  We obtained 
similar results when we analyzed replicatively senescent 
cells (Figure 1C).  At PD 65, when the cells were nearly 
completely senescent (4% BrdU incorporation, 90% 
positive for SA- βgal), miR-146a/b expression was 
higher than at PD 61, when the cells were less 
completely senescent ( 5% BrdU incorporation, 69% 
SA- βgal positive cells).  Further, miR-146a/b followed 
a similar expression pattern when we induced 
senescence by oxidative stress (hydrogen peroxide 
treatment) (Figure 1D, left lanes) or the oncogene 
RASV12 (to cause oncogene-induced senescence) 
(Figure 1D, right lanes).  Across all conditions tested, 
miRNA-146a/b expression remained low during the 
early period of senescence, when other phenotypes 
(growth arrest, SA- βgal expression, and the SASP) 
were well underway, but rose to higher levels during a 
later period after these senescence-associated 
phenotypes had been fully established.   
Figure  1.  miR146a/b  expression  increases  in  senescent
HCA2 fibroblasts. (A)  Northern blot analysis of total RNA prepa‐






















miR-146a/b suppresses IRAK-1 expression and 
reduces IL-6 and IL-8 secretion in HCA2 fibroblasts 
 
To determine the role of miR-146a/b, in the phenotypes 
of human fibroblast, we stably infected proliferating 
cells with either a control lentivirus or lentiviruses 
expressing miR-146a or miR-146b (Figure 2A).  The 
miR-146a/b overexpressing fibroblasts displayed no 
obvious morphological alterations and maintained a 
proliferation rate comparable to that of control cells 
(data not shown).  Thus, miR-146a/b did not induce a 
quiescence or senescence growth arrest. 
 
As discussed above, senescent cells robustly secrete the 
inflammatory cytokines IL-6 and IL-8.  Recent reports 
identified miR-146a/b as negative regulators of 
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reactions and cancer cell invasiveness [9, 41, 42].  We 
therefore asked, whether miR-146a/b modulated the 
secretion of inflammatory cytokines by senescent cells.  
First, we determined the effect of miR-146a/b over-
expression on IRAK1 and TRAF-6.  These proteins are 
established miR-146a/b targets and key downstream 
components of the IL-1 and Toll-like receptor signaling 
cascades, which ultimately regulate the expression of 
inflammatory cytokines such as IL-6 and IL-8 [41, 42].  
HCA2 fibroblasts that overexpressed miR-146a/b had 
markedly reduced levels of IRAK1 (Figure 2B).   
However, the levels of TRAF6 remained unaltered in 
these cells (Figure 2B).  Thus, at least in HCA2 cells, 

































Because overexpression of miR-146a/b in human 
MDA-MB-231 breast cancer cells, reduced the levels of 
secreted IL-6 and IL-8 [41] and since IRAK1 is a key 
mediator of the expression of IL-6 and IL-8, we 
compared the basal levels of secreted IL6 and IL8 in 
control and miR-146a/b overexpressing HCA2 cells.   
We collected conditioned medium (CM) from these 
cells over a 24 h period and assayed the CM for IL-6 
and IL-8 by western analysis (Figure 3A, proliferating) 
and ELISA (Figure 3B, proliferating).   We observed a 
marked reduction in basal secretion of IL-6 and IL-8 in 
the miR-146a/b overexpressing cells relative to control 
cells.  We normalized these measurements, against cell 
number and, where applicable, against the level of 
secreted IGFBP3 (Figure 3A), a protein that is not 
influenced by miR-146a/b expression [41].  






































infected)  HCA2  cells  (cntrl),  cells  infected  with  a  miR‐146a‐













and  senescence‐associated  secretion  of  IL‐6  and  IL‐8  in
HCA2 cells. (A)  Western blot analyses of TCA‐ precipitated pro‐
teins prepared from CM collected over 24 h from cells infected
with  the  lentivirus  backbone  (cntrl)  or  lentiviruses  expressing
miR‐146a (146a) or miR‐146b (146b).  The blot was analyzed for
IL‐6, IL‐8 and IGFBP3.  Equal loading was based on cell number
prior  to  collection  of  CM  and  IGFBP3  levels.  Proliferating
indicates  cells  described  in  Figure  2A.  The  same  cells  were









To determine whether miR-146a/b influenced the 
increased IL-6 and IL-8 secretion that accompanies the 
senescence, we induced the miR146a/b overexpressing 
HCA2 fibroblasts to senesce by DNA-damage 
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collected 11 days after DNA damage showed that IL-6 
and IL-8 secretion by senescent miR-146a/b-
overexpressing cells, was strikingly reduced compared 
to control senescent cells (Figure 3A-B right panel).   
RT-PCR analysis (Figure 3C), showed that miR-146a/b 
reduced the levels of IL-6 and IL-8 transcripts, 
indicating that miR-146a/b exerts these effects by 
decreasing transcription or promoting mRNA 
degradation.  Together, these observations establish that 
miR146a/b expression is sufficient to negatively 
regulate IL-6 and IL-8 secretion in both pre-senescent 
and senescent human fibroblasts.  
 
miR-146a/b expression increases only in senescent 
human fibroblasts that have robust IL-6 secretion 
 
To determine whether miR-146a/b negatively regulates 
IL-6 and IL-8 secretion in other human fibroblast 
strains, we examined BJ and IMR90 primary human 
fibroblasts.  BJ, like HCA2, fibroblasts are derived from 
neonatal foreskin, whereas IMR90 fibroblasts are 
derived from fetal lung.  Moreover, upon senescence, 
BJ and HCA2 cells express a robust SASP, whereas 
IMR90 cells express a less robust SASP, and, in 
particular, secrete less IL-6 and IL-8 [9].  We confirmed 
that senescent IMR90 cells secreted about 8-fold lower 
levels of IL-6 than senescent BJ cells when CM were 
analyzed 11 days after induction of senescence by DNA 
damage (bleomycin) (Figure 4A).  Notably, miR-146a 
levels were also substantially lower in senescent IMR90 
compared to senescent BJ cells; in fact, mi-146a was 
essentially undetectable by northern analyses in 
senescent IMR90 cells but readily detectable in BJ cells 
(Figure 4B).  Additionally, replicatively senescent 
IMR90 cells also expressed undetectable levels of miR-
146a, assayed by northern blotting, whereas miR-146a 
expression was easily detectable in near replicatively 
senescent BJ cells (Figure 4C).  Likewise, senescent 
cells of the strain WI-38, also derived from fetal lung 
and exhibiting the low SASP characteristics of IMR90 
[9], did not express detectable levels of miR-146a/b 
(data not shown).  
  
Because of the correlation between the magnitude of the 
inflammatory cytokine component of the SASP and 
miR-146a/b expression, we asked whether IMR90 
might express higher levels of miR-146a under 
conditions that induced higher inflammatory cytokine 
secretion.  We previously showed that RAS oncogene-
induced senescence results in a more robust SASP than 
damage-induced senescence [9].  We therefore 
measured the levels of IL-6 secretion (Figure 4D) and 
miR-146a/b expression (Figure 4E) in IMR90 cells 
induced to senesce by oncogenic RAS.  Oncogenic RAS 
significantly increased both IL-6 and miR-146a in 
IMR90 cells.  There was a close parallel between miR-
146a/b expression and robustness of inflammatory 
cytokine secretion. 
























Figure  4.  miR‐146a/b  increase  in  senescent  fibroblasts
that secrete high levels of inflammatory cytokines. (A) &
(B)  Proliferating BJ (PD 36) and IMR90 (PD 38) cells were treated





each  lane.  BJ  cells  reach  complete  senescence  after
approximately  70  PDs,  whereas  IMR90  cells  are  nearly
completely senescent by PD61.  (D) & (E) Proliferating IMR90
cells (PD40) were either untreated (Pro), treated with bleomycin
(DS)  or  infected  with  the  lentivirus  expressing  oncogenic  RAS
(RAS).  CM and RNA were collected 11 days after treatment or





















IL1-α upregulates miR146a/b in senescent human 
fibroblasts 
 
To determine the mechanism that connects miR-146a/b 
expression and IL-6 and IL-8 secretion in human 
fibroblasts, we explored the role of IL-1 signaling 
which is a master regulator of inflammatory cytokine 
secretion.  Because IRAK1 is both a primary target of 
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the IL-1 receptor signaling system, we tested the IL-1 
receptor ligands, IL-1α and  IL-1β, as strong candidates 
for ability to upregulate both miR-146a/b expression 
and IL-6 and IL-8 secretion.  IL-1β is a SASP 
component [9] and senescent cells contain high levels of 
membrane-bound IL-1α have also been observed in 
senescent cells (A. Orjalo, manuscript in preparation).  
We added neutralizing antibodies against IL-1α or IL-
1β to the culture medium of HCA2 cells one day after 
treatment with the DNA damaging agent bleomycin, 
and collected RNA samples 10 days later.  Northern 
analysis showed that neutralizing antibodies against IL- 
1α not IL-1β suppressed the senescence-associated 
upregulation of miR-146a (Figure 5A).  In parallel, we 
assessed IL-6 secretion levels in CM obtained in the 







































antibodies against IL-1α, but not IL-1β, suppressed the 
senescence-associated secretion of IL-6 (Figure 5B).   
Similar suppression was seen in the levels of IL-8 (data 
not shown).   
 
These findings suggest the following model (Figure 
5C): When the SASP inflammatory secretion levels are 
low (right branch), IL-1α levels and IL-1R signaling are 
low.  However, when inflammatory cytokine secretion 
is high, (left branch), high IL-1R signaling activates the 
downstream kinase IRAK1, ultimately resulting in 
activation of NFкB.  This transcription factor stimulates 
expression of the SASP cytokines, IL-6 and IL-8, as 
well as miR-146a/b.  By targeting the IRAK1 mRNA, 
miR-146a/b creates a negative feedback loop that 
restrains IRAK1 signaling and limits senescence-










































1αR)  and  the  signaling  pathway  that  involves  IRAK1  is  fully  activated.  This  activation  leads  to  the  well‐documented
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  The role of miRNAs in promoting diverse cellular 
programs such as stem cell maintenance, differentiation 
and apoptosis underscores their emerging importance as 
regulators of myriad biological processes [24-27].   
Here, we demonstrate a role for miRNA146a/b in the 
cell non-autonomous effects of cellular senescence, a 
phenomenon linked to both cancer and aging. 
 
Following multiple forms of senescence-inducing 
treatments, miR146 levels increase sharply in senescent 
HCA2 cells rising from nearly un-detectable baseline 
levels in proliferating and quiescent cells.  miR-146a/b 
expression is associated with a wide range of normal 
and pathological biology.  These miRNAs have been 
implicated in the biology of monocytic immune cells 
responding to lipopolysaccharide stimulation, human 
lung alveolar epithelial cell line responding to IL-1β 
induction, brain tissue from patients with Alzheimer’s 
disease and synovial tissue from patients with 
rheumatoid arthritis [34, 35, 43, 44].  In the majority of 
these situations, miR-146a/b acts as a negative regulator 
of inflammatory pathways.  In the immune system, 
miR-146a/b upregulation provides negative feedback on 
the innate immune system by targeting IRAK1 and 
TRAF6 [44].  These proteins are key components of the 
IL-1 and Toll-like receptor signaling system, of which 
NFкB activation is a primary downstream effector.  In 
agreement with earlier observations on immune cells, 
our previous work demonstrated that miR-146a/b 
negatively regulates NFkB activity and the inflam-
matory pathway, in breast cancer cells [41, 42].  In the 
context of senescence, the results presented here expand 
and corroborate the role of miR-146a/b as negative 
regulators of inflammation and, in particular, 
underscore its influence as a negative regulator of 
excessive IL-6 and IL-8 secretion, a hallmark of 
senescence.   
 
HCA2 human fibroblasts overexpressing miR-146a/b 
exhibited markedly decreased levels of IRAK1 as well 
as IL-6 and IL-8, under both proliferating and senescent 
conditions.  IL-6 and IL-8 expression was suppressed at 
the mRNA level, most likely a consequence of 
diminished NFкB activation following miR-146a/b-
mediated reduction in IRAK1 protein levels [41].   In 
the context of senescence, this regulation was a 
consequence of IL-1R signaling specifically activated 
by IL-1α but not IL-1β. This specificity, however, might 
be cell type-specific.   In studies of lung alveolar 
epithelial cells by Perry et al, stimulation with IL-1β 
caused a rapid increase in miR-146a levels but this did 
not impact the protein levels of either IRAK1 or TRAF6 
[43].  However, inhibitors of miR-146a did enhance the 
levels of the pro-inflammatory cytokines IL8 and 
RANTES [43].  These studies suggest that miRNA-
146a can function as a negative regulator of 
inflammation at the level of translation suppression, 
independent of the IL-1 signaling pathway involving 
IRAK1.  In contrast, miR-146a/b downregulated IRAK1 
protein levels in human fibroblasts, and thereby 
suppressed expression of IL-6 and IL-8, in agreement 
with a model whereby miR-146a/b responds to robust 
activation of the IL-1α signaling pathway and 
negatively regulates the IL-6 and IL-8 expression driven 
by that pathway (Figure 5C) [44]. 
 
We found that regulation of miR-146a/b and the IL-6 
and IL-8 inflammatory components of the SASP 
requires signaling through the IL-1R pathway.   
Neutralizing antibodies against IL-1α sharply decreased 
both IL-6 secretion and miR-146a production. In 
contrast, neutralizing antibodies against IL-1β did not 
suppress inflammatory cytokine secretion, suggesting 
that IL-1β secretion levels at senescence are not 
sufficient to produce a significant level of IL-1R 
signaling.  Taken together, these results suggest the 
model shown in Figure 5C.  In senescent cells, acti-
vation of the IL-1 receptor signaling pathway is 
dependent upon sufficiently high IL-1α levels.  In 
HCA2 cells, a wide range of conditions that induce 
senescence promote IL-1 receptor activation, whereas in 
IMR90 cells only oncogene-induced senescence results  
in sufficiently intense SASP to promote IL-6 and miR-
146 expression; senescent fibroblasts that exhibit lower 
levels of SASP secretion do not induce miR-146 (Figure 
4).   
 
Thus, miR-146a/b in senescent fibroblasts that express a 
robust SASP negatively regulates IRAK1 protein levels, 
thereby dampening the IL-1 receptor signaling pathway 
and hence the expression and secretion of inflammatory 
molecules such as IL-6 and IL-8.  This negative 
feedback loop would serve to limit the deleterious 
effects of the SASP on surrounding tissues.  This 
safeguard may be particularly important when the local 
concentration of SASP factors is high, for example 
when senescent cells accumulate in premalignant nevi 
[45] or are induced after exposure to chemotherapeutic 




Cells. Early passage HCA2 human foreskin fibroblasts 
were obtained from J Smith (University of Texas, San 
Antonio).  Early passage BJ human foreskin fibroblasts 
and IMR90 fetal lung fibroblast were obtained from 
ATCC.  Cells were cultured at 37º C in a 10% CO2 
incubator in DMEM with 10% fetal bovine serum.   
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generate lentivirus.  We defined presenescent 
(proliferative) cells, as having undergone fewer than 35 
population doublings and having a 24 h BrdU labeling 
index of ~95%.  Subconfluent cells (1500–4000/cm
2) 
were made quiescent by washing with serum-free 
medium and incubating in 0.2% serum for 4 d.   
Proliferating cells were made replicatively senescent by 
serial passage in 10% serum.  For damage induced 
senescence, cells were plated at a density of 40000/cm
2.  
Two days later the cells were treated with bleomycin 40 
µg/ml for 2 h. On the 11
th day or indicated day 
following treatment, cells were stained for the 
senescence-associated β-gal (SA- βgal) marker [46] and 
DNA synthesis was measured over a 24 h interval using 
a BrdU labeling kit ( Roche Diagnostics).  Cultures that 
had > 80% SA- βgal positive cells and ≤ 4% BrdU 
positive cells were considered senescent.  
 
Lentiviral constructs, viruses and infections.  The 
lentiviral miR-146a/b expression vectors were 
constructed as described [41].  The expression of miR-
146a/b was under control of the cytomegalovirus 
promoter.  The lentivirus encoding oncogenic RAS V12 
has been described [14].  24 h following lentiviral 
infection cells were placed under puromycin (1 µg/ml) 
selection for 4 d. 
 
Antibodies. IRAK1 ( SC 5288 ), TRAF6 (SC 8409) and 
IGFBP3 (SC 9028) antibodies were obtained from 
Santacruz Biotechnology, USA.  IL-6 (AF-206-NA), 
IL-8 (MAB208), IL-1α (MAB200) and IL-1β 
(MAB601) was obtained from R&D systems. 
 
Northern blots. Total RNA was extracted using Trizol 
(Invitrogen, Carlsbad, CA) and analyzed by northern 
blotting.  Briefly, RNA was separated on 15% TBE- 
urea polyacrylamide gels (Invitrogen, Carlsbad, CA) 
and transferred onto Hybond Plus membranes   
(Amersham, Piscataway, NJ) as previously described 
[47].  The blots were probed with an antisense miR-
146a DNA oligonucleotide, striped and reprobed with 
an antisense miR-146b DNA oligonucleotide.   
Oligonucleotides were 
32P end-labeled.  RNA loading 
was confirmed by probing for the small RNA species, 
U6.  Unless mentioned otherwise 10 µg of RNA was 
loaded in each lane.   
 
For Northern analysis of RNA harvested from cells 
treated with neutralizing antibodies, IL-1α (0.6 µg/ml) 
and IL-1β (0.8 µg/ml) antibodies were added to the 
medium one day after cells were induced to senescence 
by bleomycin.  Fresh medium was added 6 d later and 
the medium was replenished with another aliquot of the 
neutralizing antibody at the same concentration.  RNA 
was harvested 11 d after bleomycin treatment. 
 
RT PCR. Total RNA was used for RT-PCR analysis of 
IL-6 and IL-8 transcripts.  Reverse transcription was 
done using Super Script II (Invitrogen, Carlsbad,USA).  
Following reverse transcription the products were was 
amplified for 30 cycles using appropriate primers. 
 
Western Blots.  Total protein extracts were used for 
western analysis of IRAK1, TRAF6 and actin (loading 
control).  CM was prepared by washing cells 3 times in 
PBS and incubating the cells in 0.2% serum in DMEM 
medium.  CM was harvested 24 h latter and protein 
precipitated with 15% TCA overnight.  Loading was 
based on equal cell number and where appropriate 
IGFBP3 was used as a loading control.  For treatment 
with neutralizing antibodies, IL-1α (0.6 µg/ml) and IL-
1β (0.8 µg/ml) was added 24 h prior to collection of 
CM. 
 
ELISA.  CM was prepared as described above except 
cells were incubated for 24 h in serum free DMEM.   
ELISA was performed using kits and procedures from 
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